AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06659913 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Session 1: Consist of high intensity interval training performed on spinning bikes. An exercise physiologist will supervise the participants to perform a light 10 min warm-up, followed by 4 min working periods (intervals) interspersed by 3 min active breaks. The intensity should be 85-95% of estimated peak heart rate, corresponding to approximately 16 on the Borg scale (17). There will be a maximum of 10 participants in each group, depending on how many patients who are recruited for each of the two inclusion periods.I In addition, participants are encouraged to participate in the physical education at school and encouraged to perform exercise during the weekend, either with their family or friends.
Study NCT06661070 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrolysis Percutaneous Therapeutic (EPTE)
Description: EPTE device (Ionclinics, Valencia, Spain)
Study NCT06661070 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry Needling
Description: A dry needle with size 0.30 × 40 (Agupunt, Barcelona, Spain)
Study NCT06388148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medical management
Description: Medical management includes IV thrombolysis, antiplatelet, and/or anticoagulation.
Study NCT06388148 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical management
Description: Medical management includes IV thrombolysis, antiplatelet, and/or anticoagulation.
Study NCT06388148 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy
Description: Endovascular thrombectomy with stent-retriever, local aspiration, angioplasty, and/or stenting.
Study NCT06116929 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Neuropsychological assessment
Description: 3 neuropsychological assessments will be carried out at M0, M6 and M12, by the same neuropsychologist for all patients included.~Controls will undergo the same neuropsychological assessments, but only once.
Study NCT05141539 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rehabilitation assessment software
Description: In phase 2, this software will be tested in occupational therapists, and head and neck cancer patients results for reliability and validity.~In phase 3, the experiment in the oropharyngeal dysphagia specialists results in content validity, the comparison between the developed software, and VFSS and FOIS results in criterion-related validity, and the experiment in head and neck cancer patients results in reliability.
Study NCT05518994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab plus Bevacizumab
Description: 200mg sintilimab plus 3mg/kg bevacizumab every 3 weeks.
Study NCT06386367 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monastery-based health education by Buddhist monks
Description: During the three-month intervention from July to September 2022, a total of 18 health education sessions were conducted across the three intervention villages, with an average of 50 attendees per session, totaling 921 attendees across all sessions.
Study NCT06001892 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tennessee Youth Prepared for Success
Description: both 5 day classroom interventions.
Study NCT06001892 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tennessee Youth Prepared for Success
Description: both 5 day classroom interventions.
Study NCT06179355 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: manual astigmatic keratotomy
Description: manual astigmatic keratotomy using a diamond knife
Study NCT06179355 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: femtosecond laser astigmatic keratotomy
Description: astigmatic keratotomy using femtosecond lase
Study NCT04844450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-75220795
Description: JNJ-75220795 will be administered subcutaneously.
Study NCT05038189 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Gait parameters
Description: Trunk position sense as indicated by trunk reposition errors (TRE) and spine posture (thoracic and lumbar curvature) will be measured with a digital inclinometer. Gait analyses (cadence, stride length, swing phase duration, step duration and double stand duration) will be evaluated.
Study NCT04844450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered subcutaneously.
Study NCT06258265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-279
Description: TAK-279 capsule.
Study NCT06258265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-279 Placebo
Description: TAK-279 matching placebo capsule.
Study NCT06258265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin over-encapsulated tablet.
Study NCT06258265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Placebo
Description: Moxifloxacin matching placebo capsule.
Study NCT05038189 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Spine posture
Description: Trunk position sense as indicated by trunk reposition errors (TRE) and spine posture (thoracic and lumbar curvature) will be measured with a digital inclinometer. Gait analyses (cadence, stride length, swing phase duration, step duration and double stand duration) will be evaluated.
Study NCT05498792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBL0137
Description: Patient will be enrolled at 3 dose levels of CBL 0137, dose level -1 (320 mg/m²), dose level 1 (400 mg/m²), dose level 2 (540 mg/m²)
Study NCT05498792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Patient will be on Ipilimumab (1 mg/kg)
Study NCT05498792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Patient will be on Nivolumab (3 mg/kg)
Study NCT05038189 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Trunk position sense
Description: Trunk position sense as indicated by trunk reposition errors (TRE) and spine posture (thoracic and lumbar curvature) will be measured with a digital inclinometer. Gait analyses (cadence, stride length, swing phase duration, step duration and double stand duration) will be evaluated.
Study NCT05141539 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VFSS and FOIS
Description: In phase 3, this study applies VFSS and FOIS for the head and neck cancer patients for comparison with the developed rehabilitation assessment software for criterion-related validity.
Study NCT06657885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: his is a prospective, single-arm, multicentre, non-randomised phase II, pilot study designed to achieve or maintain virological success in participants who meet the prescribing criteria for lenacapavi
Description: cabotegravir initiation: daily oral route of 1 tablet 30 mg at Day 0 to week 4 Cabotegravir maintennace: Every 8 weeks (+/- 1 week) intramuscular injection from week 8 at week 48.~Lenacapavir initiation: Subcutaneous injection (927mg/3ml),ie 2 injections of 463,5mg/1,5mL in 2 distinct abdominal sites + orale route of 2 tablets of 300mg (ie 600 mg) at Day 0 and at day 1: orale route of 2 tablets of 300mg (ie 600 mg) Lenacapavir maintenance: Subcutaneous injection (927mg/3ml),ie 2 injections of 463,5mg/1,5mL in 2 distinct abdominal sites every 24 weeks (+/-1 week) from Day 0 to Week 48
Study NCT06658509 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIIT
Description: High-intensity interval training
Study NCT06658509 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SIT
Description: Sprint interval training
Study NCT06615817 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intermittent Fasting
Description: In this group, a diet based on intermittent fasting will be administered - with 14 hours of nocturnal fasting and 10 hours of feeding with a low glycemic index Mediterranean diet.
Study NCT06621732 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cutanous biopsy and blood sample
Description: cutanous biopsy and blood sample
Study NCT04794218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rVSV∆G-LASV-GPC
Description: 2 × 10\^4 pfu delivered intramuscularly
Study NCT04794218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rVSV∆G-LASV-GPC
Description: 2 × 10\^5 pfu delivered intramuscularly
Study NCT04742764 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical therapy
Description: Standard medical therapy (according to the Surviving Sepsis Campaign) will include standard monitoring (pulseoximetry, 5-lead ECG, continuous invasive blood pressure monitoring, central venous cannulation and 24 with PiCCO-technology. Norepinephrine as a vasopressor and dobutamine - if needed - as an inotrope will be administered by the attending physician.
Study NCT04794218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rVSV∆G-LASV-GPC
Description: 2 × 10\^6 pfu delivered intramuscularly
Study NCT04794218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rVSV∆G-LASV-GPC
Description: 2 × 10\^7 pfu delivered intramuscularly
Study NCT04794218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo/Diluent
Description: N/A delivered intramuscularly
Study NCT06021730 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standardized After Visit Instructions Only
Description: The intervention took a standardized approach to after visit instructions which included a customizable template that would review patients conditions, changes in any medications, and any future labs, imaging, or referrals.
Study NCT06021730 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standardized After Visit Instructions & Teach Back
Description: This intervention included the Standardized After Visit Instructions and included teach back, a process by which patients restate in their own words their understanding of their condition, what was discussed in the visit, and what potential changes were made
Study NCT05307419 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rectal suction biopsy.
Description: Suction biopsy performed
Study NCT05307419 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Full-thickness rectal biopsy.
Description: Full-thickness biopsy performed
Study NCT04803825 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heavy Slow Exercises
Description: * Load magnitude: A dumbbell as heavy as possible within the given repetitions and sets.~* Number of repetitions: week 1: 15 reps, Week 2-3: 12 reps, Week 4-5: 10 reps, Week 6-8: 8 reps, Week 9-12: 6 reps~* Number of sets: 3~* Rest between sets: 2 - 3 min.~* Number of exercise interventions: 2~* Duration of experimental period: 12 weeks~* Fractional and temporal distribution of the contraction modes per repetition and duration of one repetition: 3s concentric, 2s isometric: while change concentric/eccentric phase, 3s eccentric.~* Rest in-between repetitions: No~* Range of motion: Full range of motion~* Intervention frequency: 3 times a week, with minimum 48 h recovery time in-between.
Study NCT04803825 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal Shock wave therapy
Description: Two thousand impulses of shock waves are applied to the painful tendon, with a pressure between 1.5 and 3.0 bar (depending on what the patient tolerates). We use a power hand piece that provides energy of 0.01-0.35 mJ/mm2
Study NCT04803825 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Information and advice
Description: Information and advice are based on assessment and will comprise the standardized oral and written information. Participants will be educated regarding pain during and after activities and encouraged to be physically active. With only one session, there is great reliance on self-management. Thus, information and advice are made available through a handout.
Study NCT05931861 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T2769
Description: T2769: sodium hyaluronate 0.15%, Trehalose 3%, Naaga 2.45% in a 12.5 mL ABAK® multi-dose bottle.
Study NCT04742764 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical therapy plus cytokine removal treatment using Cytosorb, with the adsorber changed in every 12 hours
Description: Standard medical therapy, as discussed above will be applied. Furthermore, Cytosorb will be administered as soon as it is possible after randomization but not later than 2 hour (start of the treatment, T0). In a blood pump circuit in pre-haemofilter position, using a kidney replacement device of Fresenius Multifiltrate as a solo therapy or in combination with renal replacement therapy. It will be run in CVVHD, CVVHDF or CVVH mode with a 150 and 200 ml/min blood flow. Anticoagulation will be applied intravenously with heparin, low molecular weight heparin or citrate. The aim of the pump flow rate will be 100-400 mL/min, and the flow rate will be recorded. Possible shock reversal will be assessed by the physician attending. Adsorber cartridges will be changed in every 12 hours. End of the study period (Te): 12 hours after shock reversal, death of the patient, or maximum of five days, whichever happens first.
Study NCT04742764 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical therapy plus cytokine removal treatment using Cytosorb, with the adsorber changed in every 24 hours
Description: The standard medical therapy and method of Cytosorb treatment as detailed above will be applied. Adsorber cartridges will be changed in every 24 hours.
Study NCT05664828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SN132D
Description: Manganese-based macromolecular MRI contrast agent
Study NCT05129722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose combination polydiuretic therapy
Description: Low dose combination polydiuretic therapy treatment consists of:~Loop diuretic bumetanide 0.5 mg Mineralocorticoid receptor antagonist eplerenone 25 mg Sodium-glucose co-transporter 2 inhibitor (SGLT2i): empagliflozin 10mg
Study NCT05129722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator monotherapy empagliflozin
Description: Sodium-glucose co-transporter 2 inhibitor (SGLT2i): empagliflozin 10mg
Study NCT05142046 — intervention group
Intervention type: DRUG
Intervention: Fluid balance
Description: The intervention consists of classic and standardized anesthesia management of children undergoing cardiac surgery. All the data links to the fluid management will be extracted from the patient's chart in the intraoperative period as well as complications during the hospitalization in the postoperative period.
Study NCT04268706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD30.CAR-T
Description: Autologous CD30.CAR-T cells infused on Day 0 after the completion of lymphodepleting chemotherapy.
Study NCT04268706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepletion chemotherapy (30 mg/m2/day) for 3 consecutive days
Study NCT04268706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Lymphodepletion chemotherapy (70 mg/m2/day) for 3 consecutive days
Study NCT06410794 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality with Beat Saber
Description: The VR activity used in the intervention was an add-on activity that did not replace any other activities in the programme. The off-the-shelf product Beat Saber (Beat Games, Prague, The Czech Republic) is the VR game of choice in our study. In collaboration with the participating clinics a systematic VR activity plan will be developed. This includes the selection of games and designing a plan that is interesting and motivating both for patients and clinicians.
Study NCT06334783 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous tumor-infiltrating lymphocyte cells
Description: On day 0, all patients will receive autologous tumor-infiltrating lymphocyte cells administered.
Study NCT05830240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant oncolytic herpes simplex virus type 1 (R130)
Description: R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
Study NCT06306911 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aronia Melanocarpa extract
Description: Aronia Melanocarpa extract (AME) consisting of a mixture of anthocyanins and other polyphenols
Study NCT04844892 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lungpacer PROTECT Diaphragm Pacing Therapy
Description: PROTECT diaphragm pacing therapy is intended to stimulate the diaphragm to preserve and improve inspiratory muscle strength in mechanically ventilated patients.
Study NCT05667584 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hypotension prediction index derived from non-invasive arterial pressure waveforms
Description: The Hypotension Prediction Index (HPI) is an algorithm based on the complex analysis of features in high-fidelity arterial pressure waveform recordings developed to observe subtle signs that could predict the onset of hypotension in surgical and intensive care unit patients. HPI is a unitless number that ranges from 1 to 100, and as the number increases, the likelihood of a hypotensive event (MAP \<65 mm Hg for more than 1 minute) occurring in the near future increases. In a validation study on HPI conducted in patients under general anesthesia, the algorithm, at its optimal value, predicted hypotension with both sensitivity and specificity of 86% 5 minutes before the event. Measurement of the arterial pressure waveforms using a finger cuff (ClearSight) is well established.
Study NCT05667584 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: non-invasive arterial pressure waveforms
Description: ClearSight is a non-invasive hemodynamic monitoring device using digital-cuff and volume-clamp technology to obtain a continuous arterial blood pressure waveform. Continuous finger blood pressure measurement is established by wrapping the cuff around the middle phalanx of a finger. The area under the waveform curve is analyzed using a unique algorithm that serves to calculate the arterial blood pressure, stroke volume (SV) and CO.
Study NCT06447935 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: not applicable - no intervention required
Study NCT06379672 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resonance breathing
Description: Resonant breathing was used on the subjects, using nasal inhalation and oral exhalation, for a total of 12 weeks.
Study NCT05857215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amilo-5MER
Description: amilo-5MER is a 5 amino acid synthetic peptide MTADV (Methionine, Threonine, Alanine, Aspartic acid, Valine).
Study NCT05315115 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham intervention
Description: The participant's head and/or spine will be moved in ways that include passive and active movements, similar to what is done when assessing the spine by a chiropractor. The sham intervention will also include the participants moving into adjustment setup positions similar to how the chiropractor would typically set up a patient with no joint pre-loading or adjustive thrust.
Study NCT05315115 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chiropractic Care
Description: A registered chiropractor will assess the entire spine, and both sacroiliac joints will be assessed for vertebral subluxation by a registered chiropractor. The clinical indicators that will be used to assess the function of the spine before spinal adjustment intervention include assessing for joint tenderness to palpation manually palpating for a restricted intersegmental range of motion, assessing for palpable asymmetric intervertebral muscle tension, and any abnormal or blocked joint play and end-feel of the joints.
Study NCT05315115 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Physical therapy intervention
Description: The standardized treatment protocol will be provided according to the guidelines, which will include various modalities and treatment approaches, including stretching exercises; massage; strengthening exercises of weak muscles, weight-bearing, balance (static and dynamic) and gait training; electrical stimulation; treadmill use; and endurance training for the improvement of gait, motor function, strength and functional mobility in Spinal Cord Injuries children, where Conventional Therapy will be provided according to the respective needs of the individual patient.
Study NCT05315115 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy intervention
Description: The standardized treatment protocol will be provided according to the guidelines, which will include various modalities and treatment approaches, including stretching exercises; massage; strengthening exercises of weak muscles, weight-bearing, balance (static and dynamic) and gait training; electrical stimulation; treadmill use; and endurance training for the improvement of gait, motor function, strength and functional mobility in Spinal Cord Injuries children, where Conventional Therapy will be provided according to the respective needs of the individual patient.
Study NCT05368259 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AGBS
Description: The AGBS is designed to promote weight loss in individuals with obesity. The AGBS includes the Allurion Balloon, which is a temporary gastric balloon that promotes weight loss in individuals with obesity. The AGBS consists of up to 2 balloons placed during a 1-year period.